James Thomas

James is a co-founder of Thomas, McNerney & Partners and has been investing in health care companies since 1992. James previously headed Warburg Pincus LLC's medical technology private equity practice, where he had responsibility for investments in biotechnology, pharmaceutical, medical device and diagnostic companies. Prior to joining Warburg, James was a Vice President at Goldman Sachs International in London. He is currently a board member of CAS Medical Systems, Inc. (CASM), Clarus Therapeutics, Inc., Galil Medical Ltd., Keystone Dental, Inc. and Torax Medical, Inc. Historical investments include: American Medical Systems Holdings, Inc. (AMMD), Coley Pharmaceutical Group, Inc. (COLY sold to Pfizer), The Medicines Company (MDCO), NeXagen, Inc. (NXGN/NXTR sold to Gilead Sciences, Inc.), OsteoBiologics, Inc. (sold to Smith & Nephew plc), Oxford GlycoSciences, plc (OGSI sold to Celltech Group plc), Transkaryotic Therapies, Inc. (TKTX sold to Shire Pharmaceuticals Group plc), Visible Genetics, Inc. (VGIN sold to Bayer Corporation), Wright Medical Group, Inc. (WMGI), and Xomed Surgical Products, Inc. (XOMD sold to Medtronic, Inc.). James graduated magna cum laude with a B.S. in Economics from the Wharton School at the University of Pennsylvania and received an M.Sc. in Economics from the London School of Economics.